Axsome Therapeutics (AXSM) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[3], including 5 Phase 3[1], 1 Phase 4[2].
Trial NCT06568367[4] evaluates Solriamfetol 150 mg in Excessive Sleepiness with a target enrollment of 520 participants. Trial NCT06878976[5] evaluates Solriamfetol 75mg, 150 mg, or 300 mg in Binge-Eating Disorder with a target enrollment of 300 participants. Trial NCT06413433[6] evaluates Solriamfetol 150 mg in Binge-Eating Disorder with a target enrollment of 450 participants.
No Form 4 insider filings for AXSM were recorded at the SEC in the past 30 days[7].